Siemens-backed cancer therapy developer ViewRay has raised $26.7m in equity and gone public through a reverse merger with a shell company.
ViewRay, a US-based developer of radiation therapy technology backed by industrial equipment maker Siemens, has raised $26.7m from several existing stakeholders to support a reverse merger with shell company ViewRay Technologies.
Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, Montrose Capital, OrbiMed Advisors and Xeraya Capital purchased a total of 5.3 million shares in the placement.
The funding follows the $50m in debt financing secured by ViewRay from investment firm CRG last month, and supported ViewRay’s flotation on OTC Markets through…
